arrow
A

Andrea Lampis

Institute of Cancer Research
H指数:28
被引数:5,547

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancers

IDH1 R132突变或HER2阳性与胆道癌对铂类为基础的疗法的获益

2026-05-200
OAAI
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer
2024-07-121
OAAI
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

一项前瞻性共临床试验中的循环microRNA分析将MIR652-3p确定为结直肠癌中瑞格拉非尼耐药机制的反应生物标志物和驱动因素

2024-02-206
PRE
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients

MicroRNAs作为HER2-positive晚期食管-胃癌患者曲妥珠单抗治疗的生物标志物

2023-11-291
OAAI
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage
2021-11-1818
OAAI
MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer

结直肠癌中连接粘附分子A的MIR21-induced缺失促进致癌途径的激活,进展和转移

2021-07-0514
OAAI
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+Cells
2020-09-1035
OAAI
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial
2019-07-0136
OAAI
A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial
2018-12-0130
OAAI
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2018-10-02167
OAAI